-+ 0.00%
-+ 0.00%
-+ 0.00%

TAGRISSO® (OSIMERTINIB) PLUS SAVOLITINIB REDUCED THE RISK OF DISEASE PROGRESSION OR DEATH BY 45% AND THE RISK OF DEATH BY 32% IN MET-DRIVEN EGFR-MUTATED LUNG CANCER AFTER PROGRESSION ON TAGRISSO

路透·10/25/2026 15:30:02

请登录查看新闻详情